Midtown Manhattan, Pfizer building
Digest more
Realtor.com on MSN
Pfizer building developer says buckled columns were ‘freak accident’ caused by weight of new addition
Workers converting the Pfizer Building into a luxury residential tower were forced to evacuate on Tuesday after columns began to buckle.
Experts said the Pfizer building collapse likely stemmed from an engineering failure, not from the building's conversion from offices to apartments.
Following the partial floor cave-in of the old Pfizer building in Midtown on Tuesday, the developer working to convert the building into a residential complex is speaking out.
A 7% dividend yield will grab your attention, but be sure to read the fine print.
The developer of the former Pfizer building in Midtown said the building was never at risk of collapse and the repairs are fixable.
Pfizer said on Thursday that finance chief Dave Denton will leave on August 15 to return to the consumer goods industry.
Picking a good dividend stock for your portfolio can be challenging, especially when there are many attractive high-yielding options to choose from. And there's much more to consi
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 billion 2023 acquisition of Seagen failed to improve survival when compared to chemotherapy in a late-stage trial of lung cancer patients who had already tried other treatments.
Pfizer Inc. (NYSE:PFE) is one of the dividend stocks picked by financial media as investors ask whether dividend stocks are tax-efficient.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.
By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue,
HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its attractive dividend yield and long-term oncology ambitions. Analysts Rajesh Kumar and Dylan Whitfield downgraded to Hold from Buy and lowered their target forecast to $28 from $32,
